Powderly, John D.

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 12,628

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 5,231

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,222

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 463

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Fong, L., Hotson, A., Powderly, J. D., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G. M., Hellmann, M. D., Shepard, D. R., et al. (2020) · Cancer Discovery

Adenosine and Purinergic SignalingCancer Immunotherapy and Biomarkers

Cited by 352

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Jang, S., Powderly, J. D., Spira, A. I., Bakkacha, O., Loo, D., Bohac, G. C., & Sharma, M. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 46

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

Shenderov, E., Mallesara, G. H. G., Wysocki, P. J., Xu, W., Ramlau, R., Weickhardt, A. J., Zolnierek, J., Spira, A., Joshua, A. M., Powderly, J., et al. (2021) · Annals of Oncology

Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and Inhibitors

Cited by 28